Key clinical point: Prophylactic cranial irradiation improves intracranial progression-free survival and overall survival in non–small cell lung cancer.
Major finding: Prophylactic cranial irradiation reduced the risk of CNS progression (odds ratio, 0.16).
Study details: A randomized study of 84 patients with non–small cell lung cancer.
Disclosures: Dr. Arrieta reported advisory roles or provision of expert testimony for Eli Lilly, AstraZeneca, Boehringer Ingelheim, Roche, Merck, Takeda, and Bristol-Myers Squibb, and receipt of honoraria and/or research funding from AstraZeneca, Boehringer Ingelheim, Merck, Roche, and Bristol-Myers Squibb. Dr. Nasser reported receiving research grants from Bristol-Myers Squibb, AstraZeneca, Genentech, and Merck.
Arrieta O et al. WCLC 2018, Abstract MA08.02.
This Week's Must Reads
First-line avelumab/axitinib for RCC benefits wide range of patients, Choueiri TK et al. GUCS 2019, Abstract 544.
Inadequate emergency care a challenge for rural pediatric patients, Walling EB et al. J Oncol Pract. 2019 Jan 31. doi: 10.1200/JOP.18.00115.
QC measures improve with CMS Oncology Care Model, Rocque G et al. J Oncol Pract. 2019. doi: 10. 1200/JOP.18.00390.
Must Reads in CNS/Brain Cancer
Genomic characteristics of neuroblastomas linked with outcomes, Ackermann S et al. Science. 2018 Dec 7. doi: 10.1126/science.aat6768
Prophylactic cranial irradiation boosts OS in advanced NSCLC , Arrieta O et al. WCLC 2018, Abstract MA08.02.
Nivolumab plus ipilimumab ups survival in melanoma patients with brain mets, Tawbi HA et al. N Engl J Med. 2018 Aug 23. doi: 10.1056/NEJMoa1805453
Cochrane on Radiosurgery, Radiation for Brain Ca, Cochrane; 2017 Sep 25; Patil, Pricola, et al
FDA Approves First Biosimilar to Treat Cancer, FDA news release; 2017 Sep 14